Trial · NCT07885709
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
NCT07885709, Phase 2, Not yet recruiting, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC. Trials, record NCT07885709. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885709
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
- NCT number
- NCT07885709
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 100 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel, Pemetrexed, Anlotinib
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response (pCR) rate in the treatment-escalation population | At the time of definitive surgery, approximately 13 to 18 weeks after initiation of neoadjuvant therapy | pCR is defined as the absence of residual viable tumor cells in the primary lung tumor and all sampled regional lymph nodes upon systematic pathological review of the surgical specimen, per the IASLC 2020 pathological evaluation criteria. The treatment-escalation population comprises patients with ctDNA non-clearance and radiological stable disease (SD) after two cycles of neoadjuvant therapy. |
| Secondary | Major pathological response (MPR) rate in the treatment-escalation population | At the time of definitive surgery, approximately 13 to 18 weeks after initiation of neoadjuvant therapy | MPR is defined as ≤10% residual viable tumor cells in the primary lung tumor and regional lymph nodes upon pathological review of the surgical specimen; carcinoma in situ is excluded from the MPR calculation. The treatment-escalation population comprises patients with ctDNA non-clearance and radiological stable disease (SD) after two cycles of neoadjuvant therapy. |
| Secondary | Pathological complete response (pCR) rate in the intention-to-treat (ITT) population | At the time of definitive surgery, approximately 13 to 18 weeks after initiation of neoadjuvant therapy | pCR is defined as the absence of residual viable tumor cells in the primary lung tumor and all sampled regional lymph nodes upon systematic pathological review of the surgical specimen, per the IASLC 2020 pathological evaluation criteria. The ITT population comprises all enrolled patients. |
| Secondary | Major pathological response (MPR) rate in the intention-to-treat (ITT) population | At the time of definitive surgery, approximately 13 to 18 weeks after initiation of neoadjuvant therapy | MPR is defined as ≤10% residual viable tumor cells in the primary lung tumor and regional lymph nodes upon pathological review of the surgical specimen; carcinoma in situ is excluded from the MPR calculation. The ITT population comprises all enrolled patients. |
| Secondary | 2-year event-free survival (EFS) rate in the treatment-escalation and ITT populations | 2 years | EFS is defined as the time from initiation of neoadjuvant therapy to the first occurrence of any of the following, whichever occurs first: radiological disease progression per RECIST 1.1 precluding surgery, local or distant recurrence, or death from any cause |
| Secondary | 2-year overall survival (OS) rate in the treatment-escalation and ITT populations | 2 years | OS is defined as the time from initiation of neoadjuvant therapy to death from any cause. |
| Secondary | Objective response rate (ORR) in the treatment-escalation and ITT populations | After completion of neoadjuvant therapy (3-4 cycles; each cycle is 21 days), before definitive surgery | Assessed per RECIST 1.1. ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR). |
| Secondary | Disease control rate (DCR) in the treatment-escalation and ITT populations | After completion of neoadjuvant therapy (3-4 cycles; each cycle is 21 days), before definitive surgery | Assessed per RECIST 1.1. DCR is defined as the proportion of patients achieving complete response (CR), partial response (PR), or stable disease (SD). |
| Secondary | Incidence and severity of treatment-related adverse events (TRAEs) | From first dose through 90 days after the last dose of study treatment | Adverse events graded and recorded according to NCI-CTCAE version 5.0. |
| Other | ctDNA-MRD clearance rate (proportion of patients with undetectable ctDNA) at each assessment time point | At baseline (Cycle 1 Day 1), on Cycle 2 Day 14, and preoperatively on the day of surgery (each cycle is 21 days) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885709
GET https://conductscience.org/api/trials/v1/NCT07885709/registered